Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus.
- 公共卫生－已发表论文 
Anti-HBs is a well-known marker of protective capability against HBV. However, little is known about the association between the qAnti-HBs determined by immunoassays and the neutralization activity (NAT) derived from functional assays. We developed an in vitro assay for direct measurement of the NAT of human sera. The new assay was highly sensitive, with an analytical sensitivity of 9.6 ± 1.3 mIU/mL for the HBIG standard. For serum detection, the maximum fold dilution required to produce ≥50% inhibition (MDF50) of HBV infection was used as the quantitative index. In vitro NAT evaluations were conducted for a cohort of 164 HBV-free healthy individuals. The results demonstrated that the NAT positively correlated with the qAnti-HBs ( R 2 = 0.473, p < 0.001). ROC analysis indicated that the optimal cutoff value of the qAnti-HBs to discriminate significant NAT (MDF50 ≥ 8) was 62.9 mIU/mL, with an AUROC of 0.920. Additionally, we found that the qAnti-HBc was another independent parameter positively associated with the NAT ( R 2 = 0.300, p < 0.001), which suggested that antibodies against other HBV proteins generated by previous HBV exposure possibly also contribute to the NAT. In summary, the new cell-based assay provides a robust tool to analyse the anti-HBV NAT. Abbreviations: HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; Anti-HBs: Hepatitis B surface antibody; HBeAg: Hepatitis B e antigen; Anti-HBc: Hepatitis B core antibody; qAnti-HBs: quantitative hepatitis B surface antibody; qAnti-HBc: quantitative hepatitis B core antibody; qHBeAg: quantitative hepatitis B e antigen; NAT: neutralization activity; HBIG: hepatitis B immune globulin; NTCP: Na+-taurocholate cotransporting polypeptide; IRES: internal ribosome entry site; ccHBV: cell culture derived hepatitis B virus; GE/cell: genome equivalent per cell; MOI: multiplicity of infection; Dpi: day post infection; HepG2-TetOn: a HepG2-derived cell line that expresses the doxycycline-regulated transactivator; ROC: receiver operating characteristic curve; AUROC: area under receiver operating characteristic curve; LLOQ: the lower limits of quantification; MDF50: the maximum fold dilution required to produce ≥50% inhibition; IC50: half maximal inhibitory concentration.
CitationEmerging microbes & infections,2019,(1)
Showing items related by title, author, creator and subject.
杨林 (2017-03-24)慢性乙型肝炎病毒感染是世界重要的公共卫生问题，可以导致肝癌、肝硬化等终末期肝病，继而导致死亡。我国是慢乙肝高流行区，全国约有1.2亿的慢性HBV携带者，慢性乙肝患者约3000万例，HBV感染对我国国民健康造成严重威胁。本研究的主要目的在于研究自然人群慢乙肝感染者的长期转归及其相关因素，监测乙肝相关肝硬化和肝癌的发病率，并且研究成人接种乙肝疫苗对其新感染的保护以及终末期肝病发生的影响。有助于更加深入的了解和认识乙肝，并为预防和预测乙肝相关 ...
高颖 (2018-04-12)乙型肝炎病毒（HepatitisBVirus，HBV）感染是中国乃至全球重要的公共卫生问题。全球近2.4亿人为慢性乙肝病毒携带者，每年约65万人死于肝硬化、肝癌等HBV感染相关疾病（WHO）。现有的抗病毒治疗尚不能根治乙肝，接种预防性乙肝疫苗是预防HBV感染，降低人群HBsAg(HepatitisBSurfaceAntigen)携带率最为有效的手段。注射疫苗后的个体会产生不同的抗体水平，不同的抗体中和活性将决定宿主对于HBV的保护性。有 ...
C3Ig and IgC3 two-component-determined circulating immune complexes (TCIC) in patients with HCV infection Wang, SY; 王三英; Yang, TC; Zhang, JY; Xiao, SG; Peng, XX; 彭宣宪 (ELSEVIER SCIENCE BV, 2003)In the present study, we measured the levels of immunoglobulin (Ig)- and complement 3 (0)-determined circulating immune complexes (two-component-determined CIC, or TCIC) in hepatitis C virus (HCV)-infected patients. TCIC ...